We examined the influence of mutations and karyotype on conventional treatment response, specifically hematological improvement in anemia, in primary myelodysplastic syndromes (MDS).
| INTRODUCTION
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell disorders that result in dysplastic and ineffective hematopoiesis. 1 The revised international prognostic scoring system (IPSS-R) is currently the standard tool used to risk stratify MDS patients and is based on both clinical and cytogenetic data. 2 Most recently, next-generation sequencing (NGS) technology has enabled identification of mutations in MDS that adversely affect overall or leukemia-free survival, including ASXL1, TP53, EZH2, ETV6, RUNX1, WT1, SRSF2, IDH1, IDH2, DNMT3A, SETBP1, CSF3R, and others. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Several teams of investigators have now begun incorporating mutation information into clinical risk models 3, [11] [12] [13] [14] [16] [17] [18] ; the most noteworthy in this regard was the Mayo Alliance prognostic model for MDS 11 ; in the particular study that included 685 molecularlyannotated patients from the Mayo Clinic and the National Taiwan University Hospital, multivariable analysis identified monosomal karyotype (MK), "non-MK abnormalities other than single/double del (5q)," RUNX1 and ASXL1 mutations, absence of SF3B1 mutations, age > 70 years, hemoglobin <8 g/dL in women or <9 g/dL in men, 19 platelet count <75 × 10 9 /l and bone marrow blasts ≥10%, as predictors of inferior overall survival; subsequently, a four-tiered risk model and WHO Prognostic Scoring System (WPSS) were modified to include molecular data for prognostication of treated MDS patients.
When the molecular data were added to each model, a significant improvement in the predictability of each model was observed. And many patients were moved to higher or lower risk categories, particularly within the intermediate-risk IPSS-R category.
Survival risk models in MDS, like the ones mentioned above, 2, 11 are usually employed in guiding treatment selection for individual patients, which includes supportive care, drug therapy and allogeneic hematopoietic stem cell transplant (ASCT). 15 The latter is the only treatment modality with the potential for cure or substantial prolongation of life. 20 
| METHODS
The current study was approved by the institutional review board of the Mayo Clinic, Rochester, MN. Study inclusion criteria included availability of cytogenetic and NGS-derived mutation information.
The diagnosis of primary MDS was according to the 2008 World ASXL1 mutated, n (%) 98 (27) 61 (27) 37 (28) TET2 mutated, n (%) 86 (24) 49 (22) 37 (28) DNMT3A mutated, n (%) 50 (14) 36 (16) 14 (11) U2AF1 mutated, n (%) 52 (15) 23 (10) 29 (22) SRSF2 mutated, n (%) 47 (13) 33 (15) 14 (11) TP53 mutated, n (%) 43 (12) 32 (14) 11 (8) RUNX1 mutated, n (%) 36 (10) 28 (12) 8 (6) EZH2 mutated, n (%) 16 (4) 10 (4) 6 (5) IDH2 mutated, n (%) 14 (4) 13 (6) 1 (0.8) Circulating blast %, median (range)
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| Patient characteristics

| Response to treatment
Among the 225 patients with documented treatment data, 121 received treatment with HMAs (first-or subsequent-line), with 40% response rate ( Table 2) . ASXL1 mutation adversely affected response to HMAs (27% in mutated vs 48% in unmutated cases; P = 0.02, OR 2.4:1.1-5.5) ( Table 2 ). Nongenetic variables that adversely affected treatment response to HMAs included red cell 
Revised international prognostic
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7 (5) 15 (11) 17 (13) 68 (50) 29 (21) 1 (14) 3 (20) 5 (29) (15) 29 (21) 13 (32) 15 (33) 3 (14) 9 (31) 0.4 transfusion need or hemoglobin level < 10 g/dL (Table 2) ; in multivariable analysis, the association with ASXL1 mutations remained significant.
In 55 patients treated with LEN (first-or subsequent-line), 36%
responded to treatment. Isolated del(5q) was found in 27% of these patients. Treatment response to LEN was more likely in patients with SF3B1 mutations (56% vs 27%, P = 0.04; OR 0.3:0.1-0.96) but the association lost significance during multivariable analysis that included clinical predictors of response to LEN, as listed in Table 2 . As was the case with HMAs, treatment response to LEN was adversely affected by ASXL1 mutations (9% vs 43%; P = 0.04; OR 7.6:0.9-65), but also by U2AF1 mutations (0% vs 42%; P = 0.02), high risk cytogenetics (0%; P = 0.01), and presence of MK (0%; P = 0.03). Non-genetic variables predicting inferior response to LEN included age > 70 years (P = 0.03), platelet count <150 × 10 9 /l (P = 0.006), and presence of ≥5% bone marrow blasts (P = 0.002) ( mutations and failure to respond to LEN was also described in prior studies. 25, 26 In contrast, patients with SF3B1 mutations were more likely to respond to LEN (56% vs 27%), an observation that is consistent with previous reports of LEN treatment efficacy in patients with refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T). 27, 28 These observations argue against the use of LEN in MDS patients with either high risk karyotype or high risk mutations, including ASXL1 and U2AF1.
ASXL1 mutations in MDS also predicted poor response to treatment with HMAs (27% vs 48%); a similar adverse impact of ASXL1 mutations on HMA treatment response was previously reported in chronic myelomonocytic leukemia, as well. 29 In our patient cohort, no other mutations or cytogenetic risk category influenced treatment response to HMAs. Unlike previous reports reporting on favorable effect of TET2 mutations on response rates, 30, 31 especially in the absence of concomitant ASXL1 mutations, 16 we found no association between TET2 mutations and response to treatment with HMAs; among 121 patients informative for TET2 mutations, in the current patient cohort, 21% were mutated and displayed 40% response rate, compared to 41% response rate with wild-type TET2 (P = 0.9); these results remained unchanged when analysis was limited to ASXL1 unmutated cases (P = 0.4). This may be due differences in variation allele frequency (VAF) between our cohort (8%-86% VAF) and prior has been limited application of genetic information in choosing drug therapy for MDS. We hope that the current study provides practically useful information in this regard.
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